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ABSTRACT 
COMPARISON OF HFNC, BUBBLE CPAP, AND SIPAP ON AEROSOL DELIVERY 
IN NEONATES: AN IN-VITRO STUDY  
by 
Fatemah S. Sunbul 
 
Background: Aerosol drug delivery via high flow nasal cannula (HFNC), bubble 
continuous positive airway pressure (CPAP), and synchronized inspiratory positive 
airway pressure (SiPAP) has not been quantified in spontaneously breathing premature 
infants. The purpose of this study was to compare HFNC, bubble CPAP, and SiPAP on 
aerosol delivery in a simulated spontaneously breathing preterm model.  
Methods: A breath simulator was set to preterm infant settings (VT: 9 ml, RR: 50 
bpm and Ti: 0.5 sec) and connected to the trachea of an anatomical upper airway model 
of a preterm infant (DiBlasi) via collecting filter distal to the trachea. The HFNC (Fisher 
& Paykel), Bubble CPAP (Fisher & Paykel), and SiPAP (Carefusion) were attached to 
the model via their proprietary nasal cannula and set to deliver 5 cm H2O pressure. 
Albuterol sulfate (2.5 mg/0.5 mL) was aerosolized with a mesh nebulizer (Aeroneb Solo) 
positioned (1) proximal to the patient and (2) prior to the humidifier (n=5).The drug was 
eluted from the filter with 0.1 N HCl and analyzed via spectrophotometry (276 nm). Data 
were analyzed using descriptive statistics, t-tests, and analysis of variance (ANOVA), 
with p<0.05 significant.  
Results: At position 1, the trend of lower deposition across devices was not 
significant; however, in position 2, drug delivery with SiPAP was significantly lower 
compared to both HFNC (p=0.003) and bubble CPAP (p=0.008).Placement of the 
nebulizer prior to the humidifier increased deposition with all devices (p<0.05).  
 
 
Conclusion: Aerosol can be delivered via all three devices used in this study; 
however, delivery efficiency of HFNC is better than the other CPAP devices tested. 
Device selection and nebulizer position impacted aerosol delivery in this simulated model 
of a spontaneously breathing preterm infant.
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CHAPTER I  
INTRODUCTION 
Aerosol therapy is a common practice for administering medication to infants 
with pulmonary diseases. Various aerosol devices are used for administering aerosolized 
medication (Ari & Fink, 2011).Many of these devices are capable of delivering 
aerosolized medication directly to the patient or in-line with positive pressure ventilation 
(PPV) including non-invasive ventilation (NIV) (Ari, Hess, Myers, & Rau, 2009; Ari & 
Restrepo, 2012). However, aerosol device selection can be challenging when patients are 
infants, particularly because of the following anatomical and physical characteristics: 
smaller tidal volume, rapid respiratory rate, obligate nose breathing, and small pulmonary 
reserves. These factors may decrease aerosol deposition (Ari & Fink, 2011; Ari & 
Restrepo, 2012). Previous studies have shown that aerosol delivery via nebulization to 
infants has been ineffective, with less than 1% aerosol deposition (Ari & Fink, 2011; Ari 
& Restrepo, 2012). This becomes more challenging with PPV, particularly with NIV 
since aerosol delivery is further influenced by NIV settings, the position of the nebulizer 
in relation to the leak port, the aerosol generator type, and the interface used during the 
treatment (Ari & Restrepo, 2012). 
A common form of non-invasive ventilatory support that is used with infants is 
continuous positive airway pressure (CPAP). CPAP refers to the application of constant 
distending positive pressure to the airways of the spontaneously breathing infant during 
the respiratory cycle. In infants, CPAP is generally used either alone to deliver positive 
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pressure or used in conjunction with other inhaled agents (American Association of 
Respiratory Care [AARC], 2004; DiBlasi, 2009). Moreover, CPAP is a well-established 
therapeutic option for treatment of preterm infants with respiratory distress syndrome 
(RDS) (Welzing et al., 2011). CPAP is also used to treat infants with other respiratory 
disorders, including transient tachypnea of the newborn, meconium aspiration syndrome, 
pulmonary hypertension, pulmonary hemorrhage, patent ductus arteriosis (PDA), 
pulmonary edema, tracheomalacia, pulmonary infection, congenital pneumonia, central 
and obstructive apnea, and apnea of prematurity (AOP) (AARC, 2004; Courtney & 
Barrington, 2007). 
There are several CPAP delivery systems that are currently applied in practice. 
The most common CPAP devices used in infants fall under categories of continuous 
flow, variable flow, and high flow nasal cannula (HFNC), which has recently been used 
as a CPAP delivery method. Continuous flow devices include ventilator-derived nasal 
CPAP (V-NCPAP) and bubble nasal CPAP (B-NCPAP). V-NCPAP, also known as a 
conventional NCPAP, is a constant flow and constant pressure system (DiBlasi, 2009). 
The expiratory valve creates the pressure level, and it can be adjusted and maintained by 
varying the expiratory orifice size that is located in the distal expiratory limb (DiBlasi, 
2009; Kahn, Habib, & Courtney, 2008). In contrast, B-NCPAP is a constant flow and 
variable pressure system (DiBlasi, 2009). The pressure level is created by immersing the 
expiratory limb of the CPAP tubing into a water chamber, and it can be adjusted by 
changing its depth. The depth is equal to the desired CPAP level. The constant flow 
throughout the system generates bubbling in the chamber (Kahn et al., 2008). Variable 
flow nasal CPAP (VF-NCPAP), also known as an infant flow driver (IF-NCPAP), is a 
3 
 
 
 
variable-flow and constant- pressure device. Changing the flow alters the level of CPAP. 
This device is also known as “fluidic control NCPAP” because it uses fluidic control to 
maintain CPAP. During the inspiratory phase, the jet flow moves directly to the infant’s 
airway, and during the expiratory phase it shifts to the expiratory limb. This “fluidic flip” 
helps to decrease the work of breathing (WOB) during the respiratory cycle (Diblasi, 
2009; Nikischin, Petridis, Noeske, Spengler, & von Bismarck, 2011). HFNC is a new 
technique that provides continuous distending pressure through the nasal route, or 
NCPAP, to infants. Multiple studies reported the safety of utilizing HFNC as a method to 
maintain airways patency, improve gas exchange, and avoid mechanical ventilation. 
However, the airway pressure produced by HFNC is variable and unpredictable (DiBlasi, 
2009; Volsko, Fedor, Amadei, & Chatburn, 2011; Wilkinson, Andersen, O’Donnell, & 
De Paoli, 2011). 
Prophylactic treatment of aerosolized agents and therapeutic gases can be 
delivered via NCPAP. This can avert the need for endotracheal intubation and 
mechanical ventilation, and also can reduce chronic lung diseases (CLD) and improve the 
mortality rates in infants (Dhand, 2007; Kahn et al., 2008). Despite that, the current 
practice in aerosol administration for those infants on NCPAP, who require aerosolized 
medications, is disconnecting infants from the NCPAP circuit to perform a blow-by 
aerosolized treatment or to provide manual bag-mask ventilation and bagging for 
treatment. This technique loses the positive pressure that is required for lung recruitment 
due to the recurrent disconnecting of the NCPAP circuit. Other clinicians might not 
administer inhaled agents while the infant is on NCPAP. An alternative to this technique 
is administering inhaled agents in-line with NCPAP. This can help provide treatment in 
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addition to minimizing disconnections of the infant from NCPAP, thereby minimizing 
interruption of CPAP therapy and loss of pressure. However, clinicians do not use this 
alternative method because the effectiveness of aerosolized medication through the 
NCPAP system is still debated, particularly because of the lack of experimental data 
about how much aerosol is delivered to the infants via a nebulizer when used in-line with 
the NCPAP system (Farney, Kuehne, & Gibson, 2010; Smedsaas-L fvenberg, Nilsson, 
Moa, & Axelsson, 1999). In addition, research comparing various CPAP delivery devices 
is limited, and there is lack of experimental data comparing aerosol delivery via those 
devices, including VF-NCPAP, B-NCPAP, and HFNC (Kahn et al., 2008). Therefore, 
more research is required to fill this gap in the literature. For that reason, it is important to 
conduct this study to fill this gap since it gives a consistent and reliable comparison of 
aerosol drug delivery via a vibrating mesh nebulizer (VMN) in-line with three frequently 
used NCPAP devices. This study can identify the types of NCPAP generators that could 
probably increase aerosol drug delivery using a VMN. Since nebulizer position greatly 
influences aerosol drug delivery, the study can also identify the proper in-line placement 
of VMN in the circuit which could possibly optimize aerosol drug delivery during 
NCPAP therapy. Therefore, this comparison will help to direct clinicians in determining 
and choosing the most efficient method of aerosol delivery for infants while on NCPAP. 
It also will help them in decreasing the amount of work when compared with other 
methods. 
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Purpose of the Study 
The purpose of this study was to compare aerosol drug delivery using two 
different nebulizer positions with VF-NCPAP, B-NCPAP, and HFNC in a simulated 
spontaneously breathing infant model. 
Research Questions 
Q1. How do the types of CPAP systems affect aerosol drug delivery in simulated 
spontaneously breathing infants? 
Q2. Which nebulizer position results in better aerosol deposition in a simulated 
spontaneously breathing infant model? 
Research Hypothesis 
The types of CPAP systems and nebulizer positions used during aerosol therapy 
will affect aerosol deposition in simulated spontaneously breathing infants. 
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CHAPTER II  
REVIEW OF LITERATURE 
This review of literature focuses on CPAP and aerosol research in the infant 
population. The review of literature was accomplished by searching CINAHL, Web of 
Science, PubMed, Science Direct, and the Cochrane Library. The terms that were used in 
this research include the following: continuous positive airway pressure, CPAP, NCPAP, 
infants, non-invasive ventilation, bubble CPAP, ventilator-derived CPAP, Infant Flow 
CPAP, synchronized intermittent positive airway pressure (SiPAP), continuous flow 
CPAP, variable flow CPAP, high flow nasal cannula, HFNC, aerosol delivery, aerosol 
deposition, aerosolized medication, nebulization, nebulizers, small volume nebulizer 
(SVN), vibrating mesh nebulizer, VMN, bronchodilators, beta-agonists, blow-by, flow-
by, ambu bag, resuscitator bag, self-inflating bag, flow-inflating bag, and face mask. 
These terms were combined in different ways during the search. Only peer-reviewed 
articles in English published within the last 10 years (2003–2013) were included. 
However, five studies more than 10 years old were included to fulfill the purpose of this 
review. This chapter will discuss trends of using NCPAP and HFNC in infants, 
comparison of different CPAP systems, aerosol delivery in infants, and aerosol delivery 
via NCPAP systems in infants. 
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Trends of Using CPAP and HFNC in Infants 
CPAP 
The first successful clinical use of CPAP was described by Gregory and his 
colleagues in their landmark report in 1971. They were the first to devise an early CPAP 
system; it was made of an underwater seal to generate positive end expiratory pressure 
(PEEP), or simply a bubble CPAP. They conducted their study by applying CPAP 
through an endotracheal tube (n=18) or a plastic pressure chamber (n=2) in 20 premature 
infants with idiopathic respiratory distress syndrome (IRDS). The applied CPAP pressure 
in this study was between 6 to 12 cm H2O. Seventeen infants recovered from IRDS. They 
found that there is no difference in the effects of CPAP applied through either system; 
with increasing CPAP levels, PaO2 increased and minute ventilation decreased without 
affecting PaCO2, pH, arterial blood pressure, or lung compliance. Therefore, they 
concluded that CPAP increases PaO2 by improving the distribution of ventilation to 
perfusion instead of increasing alveolar ventilation (Gregory, Kitterman, Phibbs, Tooley, 
& Hamilton, 1971).  
Then, shortly after their study, Kattwinkel, Fleming, Cha, Fanaroff, andKlaus 
(1973), researchers at Case Western Reserve University and University Hospitals in 
Cleveland, Ohio, described the application of CPAP for infants by using nasal prongs. 
They modified nasopharyngeal cannulas through a chemical curing process into a nasal 
piece. The small nasal tubes had an outer diameter of 4.5 mm, a length of around 1 cm, 
and only a small resistance. The rest of the CPAP device was similar to that illustrated by 
Gregory et al. (1971). NCPAP with a level up to 12 cm H2O was applied to 22 infants 
with severe RDS whose birth weight was between 960 and 2500 gm, and whose 
8 
 
 
 
gestational age was between 28 and 36 weeks. They found that this method of applying 
CPAP was successful. Eighteen infants (82%) had a successful treatment, and they 
survived without the need for any other form of assisted ventilation. The authors 
concluded that the application of CPAP by the nasal prongs makes the treatment simple, 
safe, inexpensive, effective, and readily available to be used with infants.  
Both Gregory et al. (1971) and Kattwinkel et al. (1973) demonstrated the use of 
CPAP as safe, effective, and worth application in infants. Interest in using CPAP 
increased after that era. 
The increased use of CPAP was further demonstrated by a population-based 
cohort study performed by Roberts, Badgery-Parker, Algert, Bowen, and Nassar (2011) 
in Australia from 2001 to 2008. Their study was larger and investigated the current 
population trend in the application of CPAP in infants. The study included around 
700,000 infants whose gestational age was ≥ 24 weeks. The data was collected from live 
births and hospitalization records. They based their results on the rate of CPAP use over 
time, infants’ characteristics, gestational age, and hospital of CPAP initiation. They found 
that: from 2001 to 2008, the use of all ventilatory support in infants increased from 1,480 
to 2,486 cases involving 461 to 1,465 infants who received CPAP only. During the same 
period, the use of mechanical ventilation decreased. Moreover, CPAP use increased from 
6% to 30% in infants who were more than 32 weeks, predominantly those who began in 
non-tertiary hospitals (Roberts et al., 2011). Whereas the first two studies illustrated the 
successful use of CPAP and then NCPAP, this study provided evidence of the current 
increase of CPAP use, especially with infants whose gestational age is more than 32 
weeks. 
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Urs, Khan, and Maiya (2009), researchers at a Neonatal Intensive Care Unit, MS 
Ramaiah Medical College and Teaching Hospital, conducted a prospective observational 
study involving 50 infants with RDS requiring respiratory support. The aim of this study 
was to demonstrate the usefulness of B-NCPAP as a primary mode of respiratory support. 
The researchers used a Fisher and Paykel (F&P) B-NCPAP. They found that B-NCPAP 
is a safe and effective therapy for treating mild to moderate RDS. The effectiveness of 
using B-NCPAP was 80% (40 out of 50 infants). However, 10 infants had to be placed on 
PPV. Moreover, the B-NCPAP success rate was 100% in mild RDS, 93% in moderate 
RDS, and only 46.6% in severe RDS. Therefore, they concluded that B-NCPAP can be 
used as an effective and simple method of providing primary respiratory support for 
infants with mild to moderate RDS, and this particularly could be applied in resource-
poor settings. 
Koti, Murki, Gaddam, Reddy, and Reddy, (2010), researchers in Hyderabad, 
India, conducted a prospective analytical study of 56 preterm infants with RDS 
(gestational age 28–34 weeks) in order to determine the immediate outcomes of B-
NCPAP on those infants and to determine risk factors related to its failure. They found 
that only 14 (25%) infants failed CPAP. Factors that predict CPAP failure were no or 
limited exposure to antenatal steroids, PDA, white-out on the chest radiography, sepsis, 
pneumonia, and a Downe's score of > 7 or FiO2 ≥ 50% after 15–20 minutes of CPAP. 
They also noted that the oxygen requirement and the mortality rate were higher in infants 
who failed CPAP. Two infants developed pneumothorax, and none had CLD. Therefore, 
they concluded that infants with one of those predictor factors are at high risk of failing 
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CPAP and requiring mechanical ventilation. Nevertheless, B-NCPAP is a safe approach 
to use on preterm infants with RDS. 
CPAP was also examined by Rojas et al. (2009) in their prospective study. This 
study was conducted to evaluate the effectiveness of NCPAP following extubation, 
compared to early NCPAP alone in premature infants. Their study was a multicenter, 
randomized, controlled trial involving 278 premature infants born between 27 and 31 
weeks gestation with evidence of respiratory distress. The treatment group involved 142 
patients; these patients received the following: intubation, surfactant followed by manual 
ventilation, extubation, and then NCPAP. The control group involved 138 patients who 
were assigned to NCPAP alone. The assigned level of CPAP was 6 cm H2O using B-
NCPAP. They found that NCPAP following surfactant and very brief 
intubation/ventilation and extubation followed by NCPAP had less need for 
intubation/ventilation (26%) compared to the control group (39%), and less need for 
surfactant after the first hour of life (12%) compared with the control group (26%). 
Additionally, the treatment group had a lower occurrence of air-leak syndrome (2%) 
compared with the control group (9%), and had less CLD (49%) compared with the 
control group (59%). Therefore, they concluded that intubation, surfactant, and 
extubation (the INSURE method), without mandatory ventilation, followed by CPAP 
reduces the need for later mechanical ventilation and the incidence of air-leak syndrome, 
and appeared to be safe. It also could diminish the CLD caused by mechanical 
ventilation.  
A meta-analysis intervention review was conducted by De Paoli, Davis, Faber, 
and Morley (2008) to identify the most efficient pressure generator and nasal interface for 
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the delivery of NCPAP, reducing the need for additional respiratory support in premature 
infants. In their review, they only included randomized or quasi-randomized studies that 
compared a variety of systems of NCPAP pressure sources and/or nasal interfaces in 
premature infants. Infants who were less than 37 gestational weeks old were extubated to 
NCPAP after intermittent PPV for RDS or were placed on NCPAP therapy shortly 
following birth (within 24 hours). They found that the short binasal prongs were a more 
efficient nasal interface in averting re-intubation and respiratory failure and in decreasing 
oxygen requirement and respiratory rate (RR) compared to single nasal or 
nasopharyngeal prongs. Moreover, the Infant Flow system with short binasal prongs was 
more effective with a reported significantly lower re-intubation rate than Medicorp 
prongs (short binasal prongs as well). Infants who were placed on an Infant Flow driver 
had a significant decrease in total hospital stay days. In addition, with the use of Argyle 
prongs (short binasal prongs), a higher incidence of nasal hyperaemia was reported 
compared to Hudson prongs. Still, additional research is required that incorporates the 
longer term outcomes as well as determines the most effective short binasal prongs 
apparatus, the best CPAP pressure delivery system, and the best CPAP level to use. 
Studies comparing pressure generators using the Infant Flow system, B-NCPAP system, 
and ventilator derived CPAP system are needed as well. 
HFNC 
The clinical application of HFNC at flow rates of more than 1 LPM has increased 
with the perception that HFNC might provide benefits similar to those of NCPAP 
therapy. Spence, Murphy, Kilian, McGongigle, and Kilani (2007), researchers at St. 
Louis Children’s hospital in Missouri, used an observational study of 14 infants who 
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were placed on HFNC or NCPAP, and used the intrapharyngeal pressure (IPP) 
manometry to determine the IPP produced at varying flow rates from 1 up to 5 LPM. 
They found that an IPP of 1.70 ± 0.34 cm H2O up to 3.78 ± 0.44 cm H2O is generated on 
an average flow of 1 to 5 LPM, respectively. Therefore, they concluded that a significant 
IPP is delivered by HFNC at flows ≥ 3 LPM, so HFNC is a possible option to provide 
CPAP for infants at that flow. A linear relationship was observed between airflow and 
IPP generated at ≥ 3 LPM, so the researchers recommended further investigation via a 
larger study of the variable airway pressure generated by HFNC and its outcome on 
patient safety. 
Kubicka, Limauro, and Darnall (2008) also conducted a study to measure the 
approximate CPAP level produced by heated humidified high flow nasal cannula 
(HHHFNC) in infants. Their study included 27 infants whose gestational age was 29.1–
44.7 weeks and whose weight was 835–3735 g that were treated with HHHFNC (both 
Vapotherm 2000i and F&P devices) and excluded infants who had neuromuscular 
disorders, multiple congenital and/or chromosomal abnormalities, and severe neurologic 
impairment including a grade 3 or 4 intraventricular hemorrhage. First, they performed 
bench measurements to estimate the pressure levels that they might encounter in their 
study using an anesthesia bag as a simulation of an infant’s lung and applying three leak 
sizes around the HFNC. Then, by using a pressure transducer, they obtained 
measurements of the infants’ oral cavity pressure with the mouth closed while infants 
were on HHHFNC with a flow rates of 1-5 LPM. A small HFNC size was used (outer 
diameter 0.2 mm), and measurements were obtained using the same flow rate and FiO2 as 
ordered, without altering the flow rate or the FiO2 that the infants were on. To validate 
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their measurement method, they obtained mouth pressure measurements for five infants 
who were on B-NCPAP treatment. Their bench measurements illustrated that there was a 
linear association between the pressure generated and the flow rate for any given leak 
size. The highest pressure attained was 4.5 cm H2O with a flow rate of 8 LPM and a leak 
of 3 mm. Moreover, they stated that the results achieved with both devices (Vapotherm 
2000i and F&P) were parallel to each other, with significantly lower pressures using 
larger opening sizes. In their infant measurements they found that with the mouth open, 
no pressure was produced. With the mouth closed, a linear association was found 
between the oral cavity pressure and both flow rate and weight for infants of ≤ 1500 g. 
Therefore, they concluded that HHHFNC can generate a clinically significant level of 
CPAP. However, this CPAP level generated by HFNC is unpredictable except in smaller 
premature infants with the mouth fully closed. Moreover, the generated pressure depends 
on the flow rate and infant’s weight as well as on the size of the leak around the nasal 
cannula and the degree of mouth opening. They concluded that HFNC must not be used 
as a substitute for the delivery of CPAP because of the safety and pressure monitoring 
issues for utilizing these devices which require additional clinical trials. 
In a different study, Wilkinson, Andersen, and Holberton (2008) quantified the 
pharyngeal pressures generated by HFNC at flow rates of 2 to 8 LPM in premature 
infants. Their study sample was collected via convenience sample and included 18 stable 
infants (with a median gestational age of 34 weeks and weight of 1.6 kg) who were on 
HFNC (F&P) for treatment of RDS, CLD, or AOP.  The catheter tip of a pressure 
transducer was placed into the infants’ nasopharynx. Then the HFNC flow was increased 
to a maximum of 8 LPM and decreased to a minimum of 2 LPM, and the pharyngeal 
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pressures were obtained with and without active mouth closure. Active mouth closure 
was achieved by placing one finger under the infant’s chin. They found that there is a 
strong linear relation between the pharyngeal pressures generated by HFNC and both 
infant weight and HFNC flow rate, but not mouth closure. With increased weight, the 
pharyngeal pressure decreased; each 1 kg increase in weight decreased the average 
pressure by 1.4 cm H2O. By increasing the flow rate, the pharyngeal pressure increased: 
each 1 LPM
-1
 increase in flow increased the average pressure by 0.8 cm H2O. This 
association could be articulated as pharyngeal pressure (cmH2O) = 0.7 + 1.1 F (where F = 
flow per kg in LPM
-1
 kg
-1
). Therefore, they concluded that using HFNC at a flow rate of 
2–8 LPM in premature infants may produce a clinically significant increase in infants’ 
pharyngeal pressure. Nevertheless, the effectiveness and safety of HFNC as a mode of 
respiratory support requires verification in large clinical trials prior to its widespread 
implementation in clinical settings.  
All three studies—Spence et al.(2007), Kubicka et al.(2008), and Wilkinson et 
al.(2008)—drew similar conclusions and proved that HFNC at a flow rate of more than 1 
LPM can produce clinically significant CPAP levels in preterm infants. Both Kubicka et 
al. (2008) and Wilkinson et al. (2008) verify that there is a linear relationship between the 
infant’s weight and the flow rate with the pressure generated. However, they have 
contradictory results regarding mouth closure. Although HFNC proved to be a possible 
option to provide CPAP, a safety concern of unpredictable levels of CPAP might be 
encountered without the ability to continuously measure the CPAP level while infants are 
on HFNC, which could restrict clinicians from using HFNC as a CPAP delivery system.  
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Comparison of CPAP Systems 
V-NCPAP Versus B-NCPAP 
Many NCPAP devices are currently available. However, only a few studies 
comparing different NCPAP devices are available. A study by Tagare, Kadam, Vaidya, 
Pandit, and Patole (2009) was a pilot randomized control trial involving 30 premature 
neonates with a gestational age of less than 37 weeks and with an oxygen requirement of 
more than 30%. Tagare et al. studied the safety and efficiency of B-NCPAP versus V-
NCPAP in premature infants with moderate respiratory distress. The study results were 
comparable in both devices, B-NCPAP and V-NCPAP, including:  the mean duration of 
CPAP was 25.5 hours on V-NCPAP versus 25 hours on B-NCPAP; the success rate was 
80% in V-NCPAP versus 87% in B-NCPAP; and displacement was a common problem, 
with 67% in both groups. However, a pneumothorax developed in two neonates in the V-
NCPAP group. Therefore, they concluded that B-NCPAP could be a promising approach 
for preterm neonates with mild respiratory distress. They also noted that it is an effective 
and safe approach for respiratory distress. This study was limited by its small sample size 
and by not including the CPAP level that was used for both devices or measuring the 
respiratory parameters that could be affected by CPAP application.  
Bahman-Bijari, Malekiyan, Niknafs, and Baneshi (2011) conducted a similar 
study comparing V-NCPAP and B-NCPAP. This was a randomized prospective clinical 
study, which involved 50 preterm infants whose weight was between 1 kg and 2 kg and 
who had respiratory distress. The authors compared the effectiveness and the 
complications between B-NCPAP and V-NCPAP devices. The researchers also compared 
the survival rate, the duration of oxygen therapy, the duration of hospital stay, and 
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hospital costs. They found that both B-NCPAP and V-NCPAP had equivalent 
demographic characteristics. B-NCPAP was effective in 96% of patients versus 72% in 
V-NCPAP. B-NCPAP had lower failure rate than the V-NCPAP. The estimated survival 
rate at 24 hours was higher for B-NCPAP (100%) than for V-NCPAP (77%), and the 48-
hour survival rate was also higher for B-NCPAP (100%) than for V-NCPAP (71%). 
Moreover, higher hospital costs were found for V-NCPAP compared to B-NCPAP. 
Therefore, the authors concluded that B-NCPAP was an efficient treatment for infants 
suffering from respiratory distress and that it decreased the duration of the hospital stay. 
Compared to V-NCPAP, B-NCPAP is mainly used because of its lower cost.  
Another study conducted by Courtney, Kahn, Singh, and Habib (2011) was a 
randomized crossover study. This study involved only 18 premature infants whose weight 
was less than 1500 g and who were receiving NCPAP for mild respiratory distress. It 
compared WOB and other short-term respiratory outcomes including gas exchange 
between B-NCPAP and V-NCPAP at comparable delivered nasal prong pressures. This 
study found that there was no difference between B-NCPAP and V-NCPAP on WOB or 
on most respiratory parameters, which included tidal volume (VT), RR, phase angle, 
minute ventilation, lung compliance, heart rate, and SaO2. In addition, there was no 
significant difference in TcCO2 between those two devices; however, a higher TcO2 was 
noted with B-NCPAP compared to V-NCPAP (Courtney et al., 2011). Therefore, the 
researchers concluded that when equivalent delivered pressures are guaranteed in the 
nasal prong, B-NCPAP and V-NCPAP have similar effects on WOB and other 
respiratory parameters. Nevertheless, further research is required to investigate the 
improved oxygenation that was observed with B-NCPAP and to quantify the oscillation’s 
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high-frequency content distal to the nasal prongs in B-NCPAP. The study was limited by 
including only relatively healthy, moderately premature infants, and studying the 
outcomes after only 5 minutes on each device. Nevertheless, this study was the first to 
compare B-NCPAP and V-NCPAP in preterm infants at equivalent delivered nasal prong 
pressures. 
Kahn, Courtney, Steele, and Habib (2007) performed a study to compare the 
actual delivered pressure versus the intended pressure through intra-prong, proximal-
airway, and distal-airway via V-NCPAP and B-NCPAP devices. The settings that they 
used in their study were flow rates of 4, 6, 8, 10, and 12 LPM and NCPAP levels of 4, 6, 
and 8 cm H2O. These measurements were performed during small, large, and without 
leak conditions. The researchers found that unlike V-NCPAP, B-NCPAP delivered a 
higher pressure than the desired set levels. When these settings were tested under leak 
conditions, they found that an excess pressure was also present through prong and intra-
airway B-NCPAP. Therefore, they concluded that the ability of the ventilator to self-
adjust permits an equivalent actual versus set V-NCPAP pressure level. On the other 
hand, even with the presence of a significant nasal prong leak, the intra-prong and intra-
airway pressure generated by the B-NCPAP was higher at increasing flows than the set 
pressure. Moreover, the oscillations illustrating B-NCPAP were noticeably diminished 
between the proximal and distal airways. Thus, it is questionable that B-NCPAP creates 
lung recruitment or ventilation by this method. Finally, the set pressure of B-NCPAP that 
is determined by the depth of B-NCPAP tube is highly inaccurate; therefore, clinicians 
have to rely on intra-prong pressure measurements in order to deliver the desired 
pressure. 
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Kahn et al.’s (2008) study involved 12 preterm infants and conducted in order to 
compare the actual (delivered) intra-prong continuous positive airway pressure with the 
intended (set) NCPAP in V-NCPAP and B-NCPAP delivery and illustrated the flow 
dependence of B-NCPAP delivery in preterm infants. The researchers measured the intra-
prong pressures while increasing the flow, and then while keeping the flow constant. 
They found and concluded that in V-NCPAP the actual pressure was almost equal to the 
set pressure, whereas in B-NCPAP the actual (delivered) intra-prong pressure increased 
as the flow rate increased and was highly flow dependent.  
V-NCPAP Versus IF-NCPAP 
Bober et al. (2012) conducted a multicenter randomized controlled trial to 
compare treatment outcomes when using variable flow IF-NCPAP with constant flow V-
NCPAP among very low birth weight infants who were receiving NCPAP electively to 
prevent intubation or as a weaning from mechanical ventilation. A total of 276 infants 
whose weight was between 750 – 1500 g and a gestational age of ≤ 32 weeks were 
randomly assigned to receive the IF-NCPAP system (VIASYS) or the constant flow V-
NCPAP (baby log 8000 plus). About half (51%) of the infants were placed on an IF-
NCPAP, while 49% of the infants were placed on a constant flow V-NCPAP.  A 75% 
success rate of treatment, described as no need for intubation or re-intubation, was found 
with a non-statistically significant benefit from using an IF device. Moreover, a 
statistically significant reduction in the occurrence of nasal complications and necrotizing 
enterocolitis were seen among the IF group. 
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B-NCPAP Versus IF-NCPAP 
Malloy, Glynn, Pullar, Delaney, and Greenspan (2003) conducted a study to 
compare an IF-NCPAP device and a B-NCPAP device in 14 infants with RDS (GA ≤ 32 
weeks). Infants were placed on 5 cm H2O of CPAP on either IF-NCPAP or B-NCPAP. 
Weight loss during the first week of life, WOB, and abdominal distension were observed. 
This study found that the average number of days spent on CPAP was 8.7 for those 
infants placed on B-NCPAP and 7.7 days for those infants placed on IF-NCPAP. During 
a 7-day period, an average weight loss of 122.5 g was seen in the B-NCPAP group and 
51.75 g in the IF group. Two infants failed the B-NCPAP, while no infants failed the IF 
treatment. Therefore, they concluded that the increase in expiratory resistance from the 
continuous flow in the B-NCPAP device may cause an increase in WOB and abdominal 
distension, which explains the loss of weight trend that was seen in the first week of the 
infants’ lives. 
Liptsen et al. (2005) conducted a study in two centers—Cooper 
Hospital/University Medical Center and Schneider Children’s Hospital—in order to 
compare work of breathing and breathing asynchrony between B-NCPAP and VF-
NCPAP in premature infants. The study involved 18 preterm neonates with a birth weight 
of less than 1500 g who required NCPAP for mild respiratory distress. All infants were 
placed on B-NCPAP and VF-NCPAP at pressures of 8, 6, 4, and 0 cmH2O. A calibrated 
respiratory inductance plethysmography was used to measure the tidal volumes, and 
intrapleural pressure was used to measure the esophageal pressure. Then they calculated 
the inspiratory and resistive WOB using pressure-volume data and assessed the breathing 
asynchrony by phase angle. They found that NCPAP decreased inspiratory WOB, VT, 
20 
 
 
 
and minute ventilation. B-NCPAP, relative to 0 cmH2O, did not reduce the resistive 
WOB. Moreover, resistive WOB, RR, and phase angle were all reduced with VF-NCPAP 
compared to B-NCPAP. Therefore, they concluded that the more labored and 
asynchronous breathing observed with B-NCPAP can cause higher failure rates compared 
to VF-NCPAP. 
HFNC Versus NCPAP 
Sreenan, Lemke, Osiovich, and Hudson-Mason (2001), researchers at Royal 
Alexandra Hospital in Canada, conducted a crossover study of 40 premature infants who 
had clinically significant AOP. The researchers sought to determine the required nasal 
cannula (NC) flow to produce positive distending pressure (PDP) equal to that provided 
by NCPAP at 6 cm H2O and to compare the effectiveness of HFNC with NCPAP in the 
management of AOP. They found no difference between the PDP generated by NCPAP 
at 6 cm H2O and by NC. They also found that the NC flow needed to create a PDP 
compared to that produced with NCPAP increases with increasing infants’ weight. They 
also concluded that the difference in the frequency and duration of apnea, bradycardia, or 
desaturation between NC and NCPAP was insignificant. Finally, they noted no side 
effects of NC use such as those related to NCPAP. Therefore, they concluded that NC at 
a flow of 1– 2.5 LPM can generate PDP in infants less than 2.0 kg and that it is easy to 
perform, well-tolerable, and as effective as NCPAP in the management of AOP. For 
those reasons, they recommended using HFNC as a method of delivering PDP in infants 
with AOP. 
Campbell, Shah, Shah, and Kelly (2006) conducted a study on 40 premature 
infants (birth weight of ≤ 1250g) to compare the usefulness of CPAP created by HFNC 
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with conventional NCPAP in preventing re-intubation. Infants were randomly assigned to 
HFNC (n=20) or to IF-NCPAP (VIASYS) (n=20) immediately after extubation. They 
found that out of 20 infants who were placed on HFNC, 12 infants were re-intubated. 
Only three infants who were placed on IF failed extubation. Increase in O2 requirement, 
apnea frequency, and bradycardia after extubation were noted in the HFNC group.  
Therefore, they concluded that administering CPAP by HFNC is not as effective an 
alternative as IF-NCPAP in maintaining extubation status in premature infants.  
Shoemaker, Pierce, Yoder, and DiGeronimo (2007), researchers at two Texas 
regional medical centers, Wilford Hall USAF Medical Center and Christus Santa Rosa 
Children’s Hospital, used a retrospective study to evaluate the usage frequency, safety, 
and clinical efficacy of the humidified high flow nasal cannula (HHFNC) and to compare 
its outcome to that of NCPAP. They found that through the two study periods, the usage 
of HHFNC increased 64% following its introduction in all gestational age infants while 
the NCPAP usage decreased from 19% to 4%. Moreover, at some point in the hospital 
stay of infants who are less than 30 weeks gestational age, only 12% of them received 
NCPAP while 95% received HHFNC. In comparing both HHFNC and NCPAP, they 
found that there were no differences in adverse outcomes; however, after introduction of 
HHFNC, the number of days on ventilator per patient was decreased from 19.4 to 9.9 
days. Furthermore, intubation because of failing early NCPAP was more noticeable 
compared to early HHFNC. Therefore, they concluded that premature infants tolerate 
HHFNC well and that there were no significant differences in adverse outcomes when 
comparing infants managed by HHFNC or by NCPAP. Nevertheless, further research is 
required to identify the safety and the efficacy of HHFNC in comparison to NCPAP. 
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Wilkinson et al. (2011) conducted an intervention review that included 
randomized and quasi-randomized studies to compare the effectiveness and safety of 
HFNC instantly following birth or following extubation with other types of non-invasive 
respiratory support in premature infants. This review identified four studies comparing 
NCPAP, HHFNC, non-HHFNC, the provided flow rates, and the indication for 
respiratory support. The findings of this review include the following: using HFNC as a 
primary respiratory support following birth resulted in a similar rate of treatment failure 
as when using NCPAP; there was a higher re-intubation rate in infants treated with 
HFNC compared to infants treated with NCPAP; HHFNC and non-HHFNC had 
comparable re-intubation rates; and there was no difference in extubation success 
between the two different forms of apparatus (F&P and Vapotherm) utilized to deliver 
HHFNC. 
Aerosol Delivery in Infants 
Schüepp et al. (2005) conducted an in-vitro study to determine the optimal aerosol 
particle size for inhalation therapy in infants. They also examined the effect of breathing 
patterns and aerosol particle size on aerosol lung deposition using an infant upper airway 
lung model (Sophia Anatomical Infant Nose-Throat [SAINT] model). To measure 
aerosol delivery, a VMN (eFlow) with a facemask was used to aerosolize Budesol 
(Budesonide solution) into the upper airway of a 9-month-old lung model.  Breathing 
parameters with a fixed RR of 30 bpm and a VT of 50 ml, 100 ml, and 200 ml were used. 
Then, breathing parameters were set at a fixed VT of 100 and RR of 30 bpm, 60 bpm, and 
78 bpm, respectively. They found that with increasing VT and with increasing RR, the 
nominal dose percentage of lung deposition (5.8–30.3%) diminished. Also, a negative 
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relationship was illustrated between the mass median aerodynamic diameter (MMAD) 
(2.4–3.4 µm) with increasing VT and with increasing RR.  For all simulated breathing 
patterns, particle size distributions that were available as lung deposition have a MMAD 
of 2.4 µm and a Geometric Standard Deviation (GSD) of 1.56. Therefore, the researchers 
concluded that a MMAD of less than 2.4 µm is the optimal aerosol particle size for 
aerosol therapy for infants.  
Another study involving 12 infants (mean age 0.8 years) and 8 children (mean age 
10.8 years) with cystic fibrosis was conducted by Chua et al. (1994) to measure the effect 
of age on aerosol lung deposition. A radiolabelled normal saline was given using a 
Turrent nebulizer with a facemask for infants and with a facemask and mouthpiece for 
children. After aerosol inhalation, Planar and single-Photon emission computed 
tomography (SPECT) scans were taken. They found that in infants, the median lung 
deposition was 1.3% and that in children, the median lung deposition was 2.7%. There 
was no difference between the facemask and the mouthpiece median lung deposition in 
children. The total aerosol lung deposition was lower in infants than in older children. 
Amirav, Balanov, Gorenberg, Groshar, and Luder (2003) performed a study 
involving 14 wheezy infants with a mean age of 8 months to compare the effectiveness of 
aerosol lung deposition via a facemask or a prototype hood using a SVN.  A dose of 
99mTc Salbutamol (a radiolabelled solution) was randomly administered by either the 
facemask or the hood with the SVN using a flow rate of 8 LPM.  Gamma scintigraphy 
was used to evaluate the distribution of Salbutamol. No significant difference in total 
lung deposition between the mask and hood was found in this study. The mean total lung 
deposition with the facemask was 2.4% and with the hood was 2.6%.   
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Restrepo, Dickson, Rau, and Gardenhire (2006) conducted an in-vitro study to 
investigate the effect of increasing distance on the total inhaled drug mass using a 
standard pediatric mask compared with a T-piece. A simulated spontaneously breathing 
toddler lung model with breathing parameters of VT 60 ml, RR 30 bpm, I:E 1:2, and a 
flow rate of 3.6 LPM were used in this study. A set of five nebulizers (MistyNeb) filled 
with 3 ml of 3.0 mg of albuterol sulfate were used with a standard pediatric mask and 
with a T-piece that was capped at one end. They were positioned at the inlet of a pediatric 
test lung with a distance of 0 cm, 1 cm, and 2 cm. They found that with the facemask, the 
inhaled drug mass percentages were 2.88 ± 0.79%, 1.61 ± 0.65%, and 1.3 ± 0.42% at 0 
cm, 1 cm, and 2 cm, respectively. With the T-piece, the inhaled drug mass percentages 
were 4.14 ± 1.37%, 3.77 ± 1.04%, and 3.45 ± 0.62% at 0 cm, 1 cm, and 2 cm, 
respectively. A statistically higher inhaled drug mass was found with the T-piece 
compared to the mask. With increased distance, the inhaled drug mass significantly 
decreased with both the mask and the T-piece.  
Al Sultan et al. (2012) conducted an in-vitro study to measure aerosol drug 
delivery in a simulated pediatric lung model using a jet nebulizer (JN), a VMN, and a 
pressurized metered-dose inhaler/valved holding chamber (pMDI/VHC) in conjunction 
with a manual resuscitator bag. Using a flow rate of 10 LPM, a pediatric resuscitator bag 
(Ambu SPUR II Disposable Resuscitator) was connected to each aerosol generator, 
attached to an infant facemask, and placed firmly on the SAINT model. With each 
aerosol generator, active and passive breathing patterns were applied. Breathing 
parameters of VT 100 ml, RR 30 bpm, I:E 1:4 were used in this study. The authors found 
that the delivered mean inhaled percentage of albuterol by pMDI/VHC (19.55% and 
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27.84%)was greater than by JN (2.57% and 2.45%) or VMN (5.99% and 7.62%) in both 
passive and active breathing patterns. The VMN was more effective (with >2 fold 
greater) in aerosol delivery compared to JN. In both breathing patterns, the pMDI/VHC 
had a higher amount of lung deposition than VMN. Moreover, the same amount of 
aerosol deposition was noted using the JN during passive and active breathing. During 
active breathing, the VMN was more effective than the JN (p= 0.157 and p= 0.729, 
respectively). The greatest deposition was noted with the pMDI/VHC in the simulated 
spontaneously breathing lung model (p=0.013). 
Dubus et al. (2005), researchers in France, conducted a study to evaluate the 
aerosol delivery in a neonatal ventilation model using a conventional nebulizer 
(MistyNeb), an electronic micropump nebulizer working continuously (Aeroneb 
Professional nebulizer [APN-C]), and another APN operating synchronously with 
inspiration (Aeroneb Professional nebulizer synchronized [APN-S]). For their aerosol, 
they used 99mTc-DTPA. The neonatal settings were peak inspiratory pressure (PIP) 12-
14 mbar, PEEP 2, I:E 1:2, and RR 40 bpm. The researchers found that both APN-S and 
APN-C delivered more aerosol to the lungs than MistyNeb (14%, 12.6%, and 0.5%). 
APN-C had shorter aerosol delivery duration (2 min compared to 6 min for APN-S and 
10 min for MistyNeb). Therefore, the researchers of this study concluded that, using an 
animal model of ventilated neonates, the aerosol administration is more efficient using 
electronic micropump nebulizers.  
Aerosol Delivery via NCPAP Systems 
Similar to comparing and finding the proper NCPAP device to use with infants, 
optimal aerosol administration with NCPAP is essential in treating those infants who 
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require nebulized drugs while on NCPAP. A few studies have been conducted on this 
matter. Some of these that focus on inhaled agents via NCPAP are incorporated into this 
review. All studies that look at aerosolized bronchodilators in-line with NCPAP are 
included as well. 
In 1   , Smedsaas-L fvenberg et al., researchers at the Department of 
Paediatrics, County Hospital, Mid Sweden University in Ostersund, Sweden, modified a 
NCPAP system to allow nebulized drugs to flow through a tube to the nasal prongs and 
into the infants’ airways. The only difference between this modified NCPAP system and 
the conventional IF-NCPAP system is the integrated aerosol canal. They started their 
study by nebulizing ribavirin and surfactant to measure the aerosols’ particle size. It was 
performed at driving pressures of 2–3 bar, equivalent to a gas flow of 8–10 LPM. They 
found that the mass median diameter (MMD) of aerosolized surfactant and ribavirin was 
0.7– 0.9 µm, and less than 16% of the aerosol had a particle diameter above 1.9 µm. 
Then, they treated the infants with nebulized ribavirin and surfactant. Five infants 
(gestational age of 2 weeks to 35 weeks) with bronchiolitis were included. The infants 
were treated with CPAP for 2–9 days, and used ribavirin for 18 hours per a 24-hour 
period for 1–3 days. Only one infant had to be intubated because she demonstrated signs 
of exhaustion and increased PaCO2. They concluded that nebulized drugs via the NCPAP 
system is a feasible method for medication delivery, but recommended that a multi-center 
prospective randomized trial for aerosolized drugs with NCPAP be conducted.  A 
strength of this study is that it was the first to modify a NCPAP system to allow the 
administration of aerosolized drugs through the nasal prongs. They also performed an in-
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vitro study to measure the aerosols’ particle size, followed by a clinical trial. However, 
the sample size of this study is very small, including only five infants. 
The next study was conducted by Welzing et al. (2011), researchers at the 
Department of Neonatology, Children’s Hospital at the University of Bonn in Bonn, 
Germany, also examined the administration of an inhaled agent with NCPAP. This study 
is the first to report on combining NCPAP with inhaled nitric oxide (iNO) for treatment 
of lung hypoplasia and persistent fetal circulation in infants with very early premature 
rupture of the membrane (PPROM) and prolonged severe oligohydraminas. The 
researchers noted that before initiating NCPAP with iNO, they applied the INSURE 
method (intubation, surfactant, extubation) for those infants included in their study (n=7). 
Then researchers placed the premature infants on mechanical ventilation and iNO, which 
was started within the first hour of the infants’ lives. After that, all infants were switched 
to iNO in-line with IF-NCPAP. The authors’ major findings were that all patients in their 
study survived to discharge; six out of seven were stabilized on NCPAP with iNO only; 
only two infants showed evidence of CLD, and only one developed pneumothorax while 
on mechanical ventilation. Therefore, the authors of this study believed that combining 
NCPAP with iNO is a promising new therapeutic approach that can be efficiently and 
safely used in premature infants with lung hypoplasia and persistent fetal circulation. 
Nevertheless, the authors emphasized the need for a randomized, controlled trial that 
compares iNO combined with NCPAP to iNO with mechanical ventilation. Also, they 
stated that further research is needed focusing on whether combining iNO with NCPAP is 
effective primarily in moderate lung hypoplasia cases or in infants having severe lung 
hypoplasia. Welzing et al. showed the feasibility of combining NCPAP with iNO. 
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However, the study was limited by the small sample size, the retrospective nature of the 
study, and a missing control group.  
Finer et al. (2010), at the University of California San Diego, also conducted an 
open label, pilot study to verify the safety and usefulness of combining a prophylactic 
aerosolized Aerosurf, a synthetic surfactant, with NCPAP for use with premature 
neonates at risk of RDS. They used a VMN (Aeroneb Pro) to aerosolize 20mg/ml 
Aerosurf. Seventeen infants were enrolled in the study. The researchers found that 
Aerosurf was well-tolerated by the infants. A transient desaturation, which did not 
include bradycardia or hypotension, was observed for the duration of dosing. They also 
noted that the output rate of the Aeroneb was variable. This led to dissimilar average 
distributed drug volume per treatment per patient. All infants survived with 29.4% 
requiring consequent endotracheal surfactant replacement therapy. At 24 hours, 23.5% of 
infants were diagnosed with RDS, and at 28 days of life, 11.8% were diagnosed with 
bronchopulmonary dysplasia (BPD). The mean FiO2 was 0.4 at baseline and 0.32 at 4 
hours after treatment. Therefore, they concluded that administering Aerosurf via NCPAP 
can be safely used in premature infants at risk of RDS. This method could offer an 
alternative administration of surfactant as opposed to via an endotracheal tube. 
Nevertheless, additional research is needed to assess this delivery method. This study 
noted that the measured output rate of the Aeroneb was variable; however, they did not 
specify whether this variability was caused by the NCPAP system, the nebulizer itself, or 
the surfactant. 
Smedsaas-L fvenberg et al. (1999) conducted both an in-vitro and then a clinical 
trial. Welzing et al. (2011) and Finer et al.’s (2010) studies were clinical trials.  oth 
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Smedsaas-L fvenberg et al. (1999) and Welzing et al. (2011) used IF-NCPAP in their 
studies. Those three clinical trials are limited by their very small sample size. Unlike 
those studies, the following two studies by Fink & Kakade (2004) and Farney, Kuehne, 
and Gibson (2010) are in-vitro studies also measuring aerosol delivery via the NCPAP 
system. 
An in-vitro infant model ventilation during NCPAP was designed by Fink & 
Kakade (2004) to examine the capability of two aerosol delivery devices: the Aeroneb 
Pro and a low volume Prototype Pulmonary Drug Delivery System (PDDS) that is useful 
for positioning proximal to the infants airway. A VMN (Aerogen OnQ micropump 
aerosol generator) was combined with both devices. Differentiation between aerosol 
delivery and condensation to the infants’ model was also examined in this study. The 
researcher used a reciprocating pump animal ventilator with infant parameters (VT 10 ml, 
and respiratory rate 40 bpm), and a constant airflow of 10 LPM to create a CPAP level of 
5 cm H2O. The aerosolized drug used with the nebulizer systems in this study was 
albuterol sulfate 0.5ml (0.5%). The researcher placed the Aeroneb Pro on the inspiratory 
limb of the CPAP circuit and the PDDS nebulizer between the main flow of the CPAP 
and the nasal prongs. Then, to distinguish between aerosol delivery versus condensation, 
a filter was placed superior to the nasal prongs and the researcher performed a further run 
with the PDDS nebulizer. Fink & Kakade found that the lung deposition with Aeroneb 
Pro was 1.3 ± 0.8%. The PDDS nebulizer delivered 22.5± 1.7% when the filter was 
placed at level of the nasal prongs adaptor, and 12.8 ± 2.7% when the filter was placed 
above the nasal prongs. According to the findings of this study, the PDDS nebulizer 
delivered more drug throughout the nasal prongs of CPAP compared to the Aeroneb Pro 
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nebulizer when placed in usual orientation. Moreover, when the filter was placed superior 
to the nasal prongs, up to 40% of the Albuterol was condensate and not aerosolized. The 
high effectiveness of combining aerosol delivery with a NCPAP in this infant model 
implies potential opportunities for administering active medications to the infants’ 
airways. This study provided a strong comparison between two types of nebulizers to 
administer inhaled medication with NCPAP. 
Another similar in-vitro study was conducted by Farney, Kuehne, and Gibson 
(2010) at Nationwide Children’s Hospital in Columbus, Ohio, using a test lung to 
evaluate the particle deposition of aerosol in the systemic circuit using an Aerogen 
micropump nebulizer through a VF-NCPAP system. They used 3 ml of TC99mTc-
DTDA. Then a VMN (Aerogen micropump aerosol generator) was positioned along the 
lines of a Cardinal IF-NCPAP generator system. They placed the nebulizer both 
proximally and distally in the circuit. A simulated patient effort at a minute volume of 0.4 
L was used. They performed 15 sessions, and each session was run over 15 minutes. 
They found that when the nebulizer was positioned at the heater (n=6), the average 
medication delivery was 0.32 ± 0.36%. When the Aerogen was placed 18 inches from the 
prongs (n=9), the average medication delivery was 21.41 ± 11.49%. They found that 
when the nebulizer was located closer to the patient, the delivery of aerosolized 
medication was greater. Therefore, they anticipated a change in practice concerning the 
placement of in-line nebulizers (Farney et al., 2010). 
Both studies—Fink & Kakade (2004) and Farney et al. (2010)—used an Aerogen 
nebulizer and compared different nebulizer positions in the CPAP circuit. In Fink & 
Kakade’s study (2004), a constant flow NCPAP system was used as opposed to the VF-
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NCPAP system used in Farney et al.’s study (2010). Fink & Kakade found that aerosol 
delivery is better (22.5%) when placing the PDDS at the level of the nasal prongs 
adaptor, while Farney et al. found that the aerosol delivery is better (21.41%) when 
placing the Aerogen closer to the patient. Nevertheless, both deliver a comparable 
percentage of aerosol. 
Only one study was found that compares aerosol drug delivery with different 
CPAP systems. Zweifel (2010) conducted an in-vitro study to measure the effectiveness 
of aerosol drug delivery using different nebulizers with two different CPAP systems 
using a SAINT lung model of a 9-month-old infant. Three type of nebulizers, eFlow 
baby, Aeroneb Pro, and Cirrus, were used to nebulize 2 ml of Salbutamol (Ventolin; 
5mg/ml) in-line with Evita 4 (Drager Medical) and B-CPAP (F&P Healthcare) using 
different breathing parameters (VT 50 ml,100 ml, and 150 ml, RR 30 bpm, Ti 0.42 
second). A PEEP of 3 cm H2O was used in both CPAP devices. A face mask (Vygon) 
was attached to the nebulizers and placed between the SAINT model and the CPAP 
system. Aerosol was measured through the infant lung model. The influence of 
humidification on aerosol delivery was also examined. The researcher found that there is 
no difference in lung deposition between the two CPAP systems with the nebulizers used. 
With both CPAP systems, a significantly higher mean lung deposition (3.7% and 2.5%, 
2.1% and 2%, 1.2% and 1.6%, respectively, with each nebulizer) and a higher mean 
model deposition (46.2% and 49.7%) via the eFlow baby nebulizer was found compared 
to the Cirrus nebulizer and the Aeroneb Pro nebulizer. When the effect of humidification 
was investigated, a significantly higher mean ± standard deviation (SD) lung dose from 
the eFlow baby nebulizer through the Evita 4 was found (11.6 ± 3.5%) without 
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humidification compared with (3.7 ± 1.3%) using humidification. Higher face deposition 
was also reported with all systems. The author concluded that although the lung 
deposition was low when using efficient nebulizers, a significantly higher dose was 
delivered to the SAINT lung model. 
Two studies dealing with aerosol drug delivery via HFNC were found.  The first 
study was conducted by Bhashyam et al. (2008), researchers at the University of 
Pittsburgh in Pennsylvania. This was an in-vitro study of aerosol size and output designed 
to evaluate the possibility of delivering aerosols through nasal cannula. They utilized a 
VMN (Aerogen Solo) that was placed downstream of a heater/humidifier system, 
followed by a nasal cannula and an aerosol collection device. The study tested adult, 
pediatric, and infant cannulas with and without the use of a breathing simulator on an 
oxygen flow of 3 LPM. The researchers found that the total output of the cannula ranged 
from 8.4–25.1% and 18.6–26.9% of the loaded dose. Moreover, output doses were 
considerably higher in the pediatric and adult cannulas comparing with the infant 
cannula. The aerosol’s median diameters from the adult cannula were 2.2 ± 0.2 µm and 
1.9 ± 0.3 µm from the pediatric cannula. The size of 90% of the aerosol volume was 
smaller than 4.2 ± 0.4 µm in the adult cannula and 3.8 ± 0.5 µm in the pediatric cannula. 
The researchers concluded that a HHFNC system can efficiently deliver aerosols. 
Nevertheless, an additional study is needed to verify if this method is practical for 
pulmonary delivery. 
The second study is an in-vitro study conducted at Georgia State University by 
Ari, Harwood, Sheard, Dailey, and Fink (2011) to evaluate the delivery of aerosol with 
heliox and oxygen in a pediatric ventilation model. The parameters used in this study 
33 
 
 
 
were VT 100 ml, RR 20 bpm, and Ti 1 sec. The researchers placed a VMN (Aeroneb 
Solo) on the inspiratory inlet of a heated humidifier and attached a heated wire circuit to a 
pediatric nasal cannula (F&P Healthcare). Then they administered 2.5 mg/3ml of 
albuterol sulfate via a pediatric HFNC with 100% O2 and an 80/20% heliox mixture for a 
total of 12 runs at 3 and 6 LPM. They found that the drug deposition was equivalent 
between the heliox and O2 at 3 LPM (11.41 ± 1.54% and 10.65 ± 0.51%, respectively), 
yet was twofold greater with heliox than with O2 at 6 LPM (5.42 ± 0.54% and 1.95 ± 
0.50%, respectively). The authors of this study concluded that decreasing flow rate 
increases albuterol delivery (by twofold) yet reduces the heliox efficiency in a HFNC 
pediatric model. 
Both studies proved that aerosol can effectively be delivered through high flow 
nasal cannula using a VMN. 
Summary 
In conclusion, based on this review of literature, current research shows that 
NCPAP is a safe and effective method to be used with infants. NCPAP improves aerosol 
delivery in infants and could prevent the need for intubation and could minimize chronic 
lung injury caused by mechanical ventilation. However, few studies have compared 
different NCPAP devices, and the literature lacks studies that compare aerosol delivery in 
different NCPAP systems using an effective nebulizer device. A question remains about 
the best NCPAP device to be used to manage infants who requires CPAP support and the 
best method to deliver aerosol to those infants. Therefore, in order to improve the current 
practice, nebulization methods in conjunction with NCPAP devices should carefully be 
selected to optimize aerosol delivery while minimizing complications. Further research 
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comparing different nebulizer systems combined with NCPAP systems is required in 
order to define the optimal aerosol delivery for spontaneously breathing infants using the 
combination of a NCPAP device and a nebulizer.  
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CHAPTER III  
METHODOLOGY 
Study Variables and Design 
As represented in Figure 1, the independent variables are the three CPAP 
generators (HFNC, B-NCPAP, and SiPAP) and the VMN positions. The dependent 
(outcome) variable is the aerosol drug deposition at the tracheal level of the infant lung 
simulator. 
 
Figure 1.Organizational design of the study. 
Lung Model 
The in-vitro infant lung model that was used in this study consists of a breathing 
simulator connected to a filter (Respirgard II filter model 303, Vital signs, Inc. Totowa, 
NJ) distal to the trachea of an anatomic model of an upper airway of a preterm infant. The 
breathing parameters of the lung model were set to infant parameters of VT 9 ml, RR 50 
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bpm, and Ti 0.5 sec. (Nikishin et al., 2011). Aerosol was administered via HFNC and 
CPAP through nasal prongs to the nares of the preterm infant model. As shown in Figure 
2, the types of CPAP devices and their nasal prongs that were tested in this study include 
the following: 
(1) High flow nasal cannula (HFNC) 
(2) Bubble nasal CPAP (B-NCPAP), and  
(3) Infant Flow “sigh” positive airway pressure (SiPAP). 
  
A) SiPAP system  B) Bubble CPAP system C) HFNC system 
 
A) SiPAP  B) Bubble CPAP  C) HFNC 
Figure 2.Types of CPAP systems and nasal prongs used in the study. 
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HFNC 
The HFNC system that was used consists of a Fisher & Paykel Optiflow system 
for infants with a 10 mm ID heated circuit attached to an infant cannula (BC 2755, Fisher 
& Paykel, Healthcare Inc. Irvine, CA) and connected to a humidifier (MR 850 heater and 
MR290 chamber, Fisher & Paykel, Healthcare Inc. Irvine, CA), as shown in Figure 3. 
The humidifier was set to the non-invasive mode, which gives around 37 °C and >90% 
relative humidity, and was filled with water and attached to a flow meter using O2 tubing. 
The nasal prongs of the HFNC were inserted into the infant model’s nose. The pressure 
was measured using a flow rate of 5–6 LPM (Wilkinson et al., 2011) by a continuous 
recording manometer and was adjusted to deliver a pressure of 5 cm H2O.  A flow rate of 
3 LPM generated a pressure level of 5 cmH2O. 
 
Figure 3.Experimintal set-up with HFNC. 
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B-NCPAP 
The lung model of the B-NCPAP system that was used in this study consists of a 
bubble CPAP generator; a pressure manifold (BC163-10, Fisher & Paykel, Healthcare 
Inc., Irvine, CA); a humidifier (MR 850 heater and MR290 chamber, Fisher & Paykel, 
Healthcare Inc., Irvine, CA);a bubble CPAP circuit; FlexiTrunk nasal tubing (BC181-08, 
Fisher & Paykel, Healthcare Inc., Irvine, CA), which contains an inspiratory and an 
expiratory limb and nasal prongs (Figure 4). Size 3.0 mm/ 2.0 mm nasal prongs (BC 
3020-10 Fisher & Paykel, Healthcare Inc., Irvine, CA) were used in this model. The 
expiratory limb was attached to a bubble CPAP device, and the inspiratory limb was 
attached to a heated humidifier.  
The inspiratory limb of the nasal tubing was attached to the humidifier using a 
heated B-NCPAP circuit, and the B-NCPAP pressure manifold was connected to an air 
outlet (flow meter) by O2 tubing. The humidifier was set at 37 °C using the non-invasive 
mode and was filled with water. The bubble CPAP generator was also filled with water. 
The depth of the water determines the CPAP level (P= 5 cm H2O). The bubble CPAP 
generator was connected to a circuit and was attached to the expiratory limb of the 
FlexiTrunk nasal tubing that had the nasal prongs. The nasal prongs of the B-NCPAP 
were inserted into the model’s nose. The intra-prong pressure also was adjusted by 
titrating the flow meter and was measured by a pressure manometer (P= 5 cm H2O) 
(Nikischin et al., 2011). In this model, a flow of 4 LPM generated a pressure level of 5 
cm H2O. 
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Figure 4.Experimental set-up with bubble NCPAP. 
 
SiPAP 
As shown in Figure 5, the IF-NCPAP lung model consists of a flow-derived 
CPAP device (Infant Flow SiPAP, CareFusion, Yorba Linda, CA) connected to a circuit 
attached to a humidifier by an adaptor. The humidifier was filled with water and the 
temperature of the humidifier was set at 37 °C using the non-invasive mode. The 
humidifier also was attached to the temperature probe connected to a CPAP heated circuit 
using the inspiratory limb of the infant circuit (Infant Flow LP generator7772020LP, 
CareFusion, Yorba Linda, CA) that has the nasal prongs (777000XS, CareFusion, Yorba 
Linda, CA). The nasal prongs were connected to the nares of the infant lung model. The 
IF-CPAP flow was adjusted to generate 5 cm H2O pressure; P low was set at 9LPM, and 
P high was set at 2 LPM (DiBlasi, 2009), and the intra-prong pressure was measured by a 
continuous recording pressure manometer. 
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Figure 5.Experimental set-up with SiPAP. 
 
Nebulizer Type and Dose 
A vibrating mesh nebulizer (VMN) (Aeroneb Solo, Galway, Ireland) was tested in 
this study using a 2.5 mg/ 0.5 ml (0.5%) unit dose of albuterol (Fink & Kakade, 2004). 
The nebulizer was placed in two different positions in the inspiratory limb of the CPAP 
systems. The VMN was connected to each system and run until the end of nebulization. 
Nebulizer Position 
As shown in Figure 3, two nebulizer positions were tested in the HFNC model. 
For the first position (nebulizer position 1), the VMN was placed after the humidifier, 
between the humidifier and the nasal cannula tubing. For the second position (nebulizer 
position 2), the VMN was placed prior to the humidifier. In both positions, the nebulizer 
was run with a flow that generates similar levels of prong pressure as the two CPAP 
setups. 
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Two positions were utilized for both the B-NCPAP system and the SiPAP system, 
as presented in Figures 4 and 5, respectively. In the first position, the VMN was placed 
proximal to the infant model, in the middle of the circuit between the humidifier and the 
nasal tubing. The second position was prior to the humidifier.   
 
Data Collection 
A filter was placed between the lung simulator and the trachea of the DiBlasi 
model.  After each run was completed, the filter was detached from the circuit and soaked 
with 0.1 N HCl to remove the drug. Then the albuterol drug deposition was analyzed by a 
spectrophotometery (Beckman Instruments, Fullerton, CA) at 276 nm. Each condition 
was tested five times (n=5). 
Data Analysis 
The percentage of aerosol deposition was measured and reported. A one-way 
analysis of variance (ANOVA) was used to compare the mean aerosol deposition with 
each system. A paired t-test was used to compare the two nebulizer positions used with 
the HFNC, the B-NCPAP, and the SiPAP. A p-value of < 0.05 was considered to be 
statistically significant. 
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CHAPTER IV  
RESULTS 
The inhaled mass and percentage of nominal dose (mean ± SD) deposited distal to 
the trachea obtained with each CPAP device are represented in Table 1 and Table 2, 
respectively. 
 
Table1 
Mean ± SD of the Inhaled Mass Deposited Distal to the Trachea, Using HFNC, Bubble 
CPAP and SiPAP at Two Positions 
 HFNC Bubble CPAP SiPAP P-values 
Position 1: 
Proximal to the patient 
22 ± 6.5 17 ± 4.0 14 ± 4.9 0.101 
Position 2: 
Prior to the humidifier 
32 ± 4.5 30 ± 6.1 19 ± 2.7 0.002 
P-values 0.43 0.007 0.130  
 
Table 2  
Mean Lung Dose Percent ± SD Delivered Distal to the Trachea with Each Device, Using 
Two Nebulizer Positions 
 HFNC Bubble CPAP SiPAP P-values 
Position 1: 
Proximal to the patient (%) 
0.90 ± 0.26 0.70 ± 0.16 0.59 ± 0.19 0.098 
Position 2: 
Prior to the humidifier (%) 
1.30 ± 0.17 1.24 ± 0.24 0.79 ± 0.11 0.002 
P-values 0.43 0.03 0.13  
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Effect of Nebulizer Position on Aerosol Drug Deposition 
The results of this study showed that placement of the nebulizer prior to the 
humidifier increased aerosol deposition with all the devices tested in this study. While the 
trend to lower deposition across devices was not significant at Position 1 (p=0.098), 
differences in the mean inhaled percentage of dose delivered by each device at Position 2 
were statistically significant (p=0.002). Drug delivery with SiPAP was significantly less 
than with both HFNC (p=0.003) and bubble CPAP (p=0.008) at Position 2. No 
significant difference was found between HFNC and bubble CPAP on aerosol delivery at 
Position 2 (p=0.865). 
Effect of HFNC and CPAP Systems on Aerosol Drug Delivery 
The present study demonstrates that HFNC consistently delivered more drug than 
bubble CPAP and SiPAP under all conditions tested. Regardless of the nebulizer position 
used in this study, SiPAP was the least efficient device in terms of aerosol drug delivery 
in this simulated spontaneously breathing infant model. HFNC, bubble CPAP, and SiPAP 
were most efficient at Position 2. As distance between the nebulizer and the patient 
increased, aerosol delivery with each device improved. Although not significant, there 
was a meaningful increase on aerosol deposition with SiPAP (p=0.130) when the 
nebulizer was placed distal to the humidifier. As shown in Figure 6, the increase in the 
amount of inhaled drug mass obtained with bubble CPAP and HFNC at Position 2 was 
statistically significant (p=0.007 and p=0.43, respectively).  
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Figure 6.The mean inhaled mass (µg) ± SD of albuterol deposited distal to the trachea 
with HFNC, Bubble CPAP, and SiPAP using two nebulizer positions. * indicates a 
statistically significant difference (p< 0.05). 
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CHAPTER V  
DISCUSSION 
HFNC, bubble CPAP, and SiPAP are commonly used CPAP delivery systems in 
clinical settings. These devices can also be used by clinicians to deliver aerosolized 
treatments via a VMN.A few studies have reported delivery of inhaled agents (i.e., iNO, 
surfactant) via CPAP systems. However, research indicating the efficiency of those 
delivery devices in aerosol drug delivery is limited and the effect of the various CPAP 
devices and nebulizer positions is unknown. Therefore, this study compared aerosol drug 
delivery using HFNC, bubble CPAP, and SiPAP and investigated the effect of nebulizer 
position on aerosol deposition with those devices in a simulated spontaneously breathing 
preterm model. This study found that HFNC was the most efficient of the three systems 
in terms of drug delivery. SiPAP delivered the least amount of aerosolized medication. In 
addition, placing the nebulizer prior to the humidifier increased aerosol deposition with 
all the devices tested in this study. 
Effect of Nebulizer Position on Aerosol Drug Deposition 
Previous research shows that the nebulizer’s position on the circuit greatly affects 
aerosol drug delivery during mechanical ventilation and that nebulizer placement prior to 
the humidifier increases aerosol deposition in a mechanically ventilated pediatric lung 
model (Ari et al., 2010). This study also found that placing the nebulizer prior to the 
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humidifier consistently delivered a higher drug mass percentage compared to placing it 
proximal to the nasal interface with all HFNC and CPAP systems. 
Consistent with Ari et al. (2010), this study finds that placing the VMN in the 
circuit prior to the humidifier improves aerosol drug delivery compared to the proximal 
position. Ari et al. evaluated the effect of nebulizer position on aerosol drug delivery 
during mechanical ventilation using adult and pediatric lung models. They used a VMN 
to nebulize 2.5 mg of albuterol sulfate in 3 ml of normal saline. The VMN was placed (1) 
directly on the y-piece adaptor and (2) at the humidifier inlet. A heated humidifier and 
circuit were used in both lung models. They found that when the VMN was placed prior 
to the humidifier, the drug delivery increased in both lung models (21.4 ± 0.4% and 10.6 
± 0.3, respectively), compared to the proximal position (9.7± 0.6 % and 8.4 ± 0.2%, 
respectively), with a bias flow of 5 LPM. Drug delivery was higher with the adult lung 
model than with the pediatric lung model. 
Even though both this study and Ari et al. (2010) study similarly found that VMN 
is more efficient when it was placed prior to the humidifier, the present study found a 
lower drug deposition with both nebulizer positions. The main difference between the 
two studies is that Ari et al. evaluated aerosol drug delivery during mechanical ventilation 
with an adult and a pediatric circuit, as opposed this study’s use of infant-size HFNC and 
CPAP systems with a smaller diameter circuit. Moreover, using a dual-chamber test lung, 
adult parameters used in the Ari et al. study were a VT of 500 ml, a PEEP of 5 cm H2O, 
an RR of 20 bpm, and a peak inspiratory flow of 60 LPM. The pediatric parameters they 
used were a VT of 100 ml, a PEEP of 5 cm H2O, an RR of 20 bpm, and a Ti of 1 sec. In 
contrast, this study used the DiBlasi lung model, and the infant parameters included a 
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higher rate (50 bpm) and a lower VT (9 ml). These differences in study design could 
account for the improved drug deposition found by Ari et al. In addition, Ari et al. used 
an ETT size of 8 mm and 5 mm for the adult and pediatric models, respectively; in 
contrast, this study used nasal prongs with smaller internal diameters. The interface’s 
internal diameter can impact aerosol delivery. Finally, a similar VMN was used in both 
studies, yet Ari et al. used a higher drug dose (3 ml) than the one used in this study (0.5 
ml).   
Effect of HFNC and CPAP Systems on Aerosol Delivery 
While research comparing aerosol drug delivery through HFNC, bubble CPAP, 
and SiPAP is lacking, only two studies have assessed the effectiveness of aerosol drug 
delivery through HFNC (Ari et al., 2011; Bhashyam et al., 2008). Moreover, only one 
study has compared aerosol delivery through two different CPAP systems, yet that study 
included V-CPAP and B-CPAP (Zweifel, 2010). 
HFNC 
In neonates, a flow rate of more than 1–2 LPM is considered high (Lee, Rehder, 
Williford, Cheifetz, & Turner, 2013). Mosca, Colnaghi, Agosti, and Fumagalli (2012) 
documented a recent increase in the use of HFNC as an alternative respiratory support 
modality to NCPAP for preterm infants. The current literature shows that the precise 
mechanism of action for HFNC needs to be clarified and that the evidence supporting the 
superiority of HFNC over CPAP is lacking. In addition, researchers have documented 
inconsistent evidence supporting HFNC’s safety, predominantly because of the 
unpredictable level of positive airway pressure delivered to premature infants (Lee et al., 
2013). Despite that, HFNC is an attractive option in the treatment of infants with 
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pulmonary diseases because it is easy to use, well tolerated by infants, and may decrease 
septum erosion with lighter pressure applied to the infant nose (Mosca et al., 2012). 
This study examined the effect of HFNC on aerosol drug delivery while ensuring 
the same delivered CPAP level to the other two CPAP systems used in this study. 
Aerosol drug delivery through HFNC increased when the nebulizer position was changed 
from the proximal to the distal position (0.9 ± 0.26% and 1.3 ± 0.17%, respectively). 
Still, apart from the nebulizer positions tested in this study, the highest drug deposition 
was found in the HFNC system compared to both the bubble CPAP and the SiPAP. 
Bhashyam et al. (2008) examined the aerosol deposition in HFNC, using infant, 
pediatric, and adult size cannulas and found that the total drug output ranged from 8.4 ± 
2.4% (without using a Harvard lung) to 18.6 ± 4.0% (with a Harvard lung). Their study 
used the same type of mesh nebulizer as this study. Like in this study, Bhashyam et al. 
placed the nebulizer downstream in the inspiratory limb after the humidifier, and both 
studies used a flow rate of 3 LPM. Bhashyam et al. used the following infant lung 
parameters: RR 25 bpm and Ti 50/50, and due to a limitation in the simulator used in 
their study, a pediatric VT of 150 ml was used with the infants’ cannula. Moreover, their 
study used around 2mCi of Technetium (Tc-99m) DTPA in 4 ml of deionized water as 
their aerosolized drug, and the nebulizer ran approximately 10–13 minutes during each 
run. In contrast, the present study only used 0.5 ml of albuterol, which required a shorter 
nebulization time. Using a higher amount of drug and a higher VT may have increased 
aerosol drug delivery. 
Ari et al. (2011) also reported higher drug deposition compared to this study. 
Their results were similar to those of Bhashyam et al. (2008) when a low flow of 3 LPM 
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was used. In Ari et al.’s study, the percentage of inhaled dose with O2 at 3 LPM was 
10.65 ± 0.51 %, and was 1.95 ± 0.5% with O2 flow rate of 6 LPM, as compared to 1.3 ± 
0.17% with a flow of 3 LPM in this study. Ari et al. examined drug delivery in a pediatric 
HFNC at a flow rate of 3 LPM and 6 LPM, whereas this study used infant HFNC with a 
smaller internal diameter at a flow rate of 3 LPM. Similar to this study, Ari et al. also 
used an Aerogen Solo, which was placed prior to the humidifier. However, 2.5 mg/ 3 ml 
albuterol sulfate was used to run the nebulizer as opposed to the 0.5 ml used in this study. 
Furthermore, they used a breath simulator that consisted of a ventilator and a dual-
chamber test lung as opposed to the infant lung model with an upper airway model that 
was used in this study. Ari et al. noted that when the flow rate via the HFNC was 
increased, the inhaled dose percentage decreased, which could explain the finding in the 
present study of low drug deposition. 
B-NCPAP 
Recently, the use of bubble NCPAP has increased, particularly because B-NCPAP 
is safe, simple, easy to operate, inexpensive, does not require an electrical power source 
(DiBlasi, 2009; Kahn et al., 2008). Previous research has found that B-NCPAP may 
decrease the need for intubation and lower the incidence of CLD (Courtney et al., 2011; 
DiBlasi, 2011; Kahn et al., 2008). Moreover, B-NCPAP has become a favored device due 
to the perception the oscillation delivered by continuous bubbling of the device may be 
beneficial and may contribute to improving the gas exchange and reducing the WOB 
(Kahn et al., 2008; Liptsen et al., 2005). In addition, studies have shown that this 
continuous oscillating CPAP, delivered by bubble CPAP, may also improve lung 
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recruitment without increasing the MAP and may minimize respiratory resistance 
(Manilal-Reddy & Al-Jumaily, 2009). 
This study examined aerosol drug delivery through bubble CPAP and found that it 
was the second highest after the HFNC in both the proximal and distal positions, 0.7% 
and 1.24%, respectively. 
Zweifel (2010) similarly found low drug deposition in the bubble CPAP system 
when the nebulizer was placed in the proximal position. Zweifel used a SAINT lung 
model with pediatric parameters of VT 100 ml, RR 30 bpm, and Ti 0.42 sec., as compared 
with the DiBlasi lung model used in this study with breathing parameters of VT 9 ml, RR 
50 bpm, and Ti 0.5 sec. These differences in breathing parameters in both studies (with a 
lower VT and a higher RR) may explain the lower deposition with the bubble CPAP 
found in this study. Zweifel administered 2 ml of ventolin through a face mask to the 
lung model using three different nebulizers and two CPAP systems, whereas the present 
study used 0.5 ml albuterol sulfate that was administered through a nasal interface using a 
VMN only. Zweifel found that the lung deposition through the bubble CPAP device 
using a different nebulizer (Aeroneb pro) in the proximal position was about 1.6 ± 0.3%., 
as compared to 0.7± 0.16% in this study. 
SiPAP 
A second generation of NIV is the infant flow “sigh” positive airway pressure 
system (SiPAP). The main difference between the SiPAP and other IF-CPAP and NIV 
devices is that SiPAP permits the infant to continuously breathe at two different CPAP 
levels. The possible benefits of using these two pressures are reduced breathing 
asynchrony and WOB during both inspiration and expiration (Liptsen et al., 2005; 
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Nikischin et al., 2011). Other reported advantages of these intermittent “sigh” breaths are 
improved alveolar recruitment and gas exchange, maintaining FRC at the end of 
expiration, providing airflow stimulation to avert apnea, and decreasing the need for 
invasive ventilation (DiBlasi, 2009, 2011). No studies investigating delivery efficiency of 
SiPAP in the treatment of infants with pulmonary diseases were found that could be 
compared to the results of this study. 
Clinical Implications 
This study examined aerosol drug deposition with three of the most commonly 
used CPAP delivery devices in clinical settings. While SiPAP is less efficient in aerosol 
drug delivery compared to bubble CPAP and HFNC, HFNC is the most efficient device 
tested in this in-vitro study.  
The use of an in-line VMN has increased in practice. Using an in-line VMN with 
CPAP prevents the recurrent disconnection of the nasal interface to provide aerosol 
treatment, which prevents interrupting and losing the positive pressure required with 
CPAP therapy. This could minimize an infant’s distress and agitation during the 
administration of aerosolized treatment. In addition, rather than placing the nebulizer in 
the proximal position, placing the nebulizer prior to the humidifier can minimize 
sputtering and condensation produced in the circuit. In addition, at the level of the nasal 
interface, this position permits the larger particles’ rainout to be drained in the humidifier 
before entering the inspiratory limb (Ari et al., 2011). However, the effect of the rainout 
on the collecting filter was eliminated in this study by draining out the condensate from 
the circuit. 
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In addition to increasing aerosol drug deposition, placing the nebulizer prior to the 
humidifier can prevent adding the nebulizer’s weight to the nasal interface, as occurs 
when it is placed in the proximal position. This nebulizer position may also help in 
keeping the aerosol in the circuit as a reservoir during the expiratory phase, rather than 
allowing it to leave the system through the leak port in the expiratory limb, as occurs in 
the proximal position. This also could explain why higher drug deposition was found 
with the HFNC device compared to both the bubble CPAP device and the SiPAP device. 
Unlike these latter two systems, there is no exhalation port or expiratory limb in the 
HFNC system, which could cause aerosol particles to stay in the system during the 
respiratory cycle and then be directed to the nose during inspiration, as opposed to 
leaving the system through the exhalation port in both the bubble CPAP and SiPAP 
devices. 
Limitations of the Study 
Even though this study examined aerosol drug delivery via three CPAP delivery 
devices using two positions with a very effective nebulizer, only one CPAP/flow level 
and one set of breathing parameters of a relatively healthy premature infant lung was 
used. Drug delivery can be affected greatly by the size of the airway, the lung volume, 
RR, inspiratory flow, and the breathing pattern of the patient (Ari & Fink, 2011). In 
addition, a constant set pressure and intra-prong pressure were maintained on all devices 
tested in this study, except the intratracheal pressure. Previous studies have shown that 
the actual delivered intra-airway pressure could be different from the set pressure with 
CPAP systems (Kahn et al., 2007). Moreover, a variety of drug delivery devices are used 
in clinical settings, but this study examined only one type of nebulizer. Lastly, this is an 
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in-vitro study and thus does not appraise the actual clinical response of infants receiving 
CPAP therapy. 
Recommendations for Future Research 
Further studies that investigate aerosol drug delivery and measure aerosol particle 
size using different nebulizers and/or pMDIs, different interfaces, different breathing 
parameters, and different CPAP/ flow settings would guide clinicians in proper methods 
to increase drug deposition in neonates. Moreover, the effect of humidification on aerosol 
drug delivery was not examined in this study, so conducting a similar study to measure 
the aerosol drug delivery with and without humidification is suggested. In addition, 
because sigh breaths with SiPAP improve lung recruitment, an investigation of the 
impact of sigh breaths during SiPAP on aerosol drug delivery is recommended. Lastly, 
maintaining a continuous CPAP level by avoiding circuit disconnection is crucial during 
CPAP therapy in order to maintain lung recruitment and decrease infants’ disturbance, so 
further studies are needed that evaluate clinical efficiency in administering aerosol via 
CPAP. 
Conclusion 
Aerosolized medications can effectively be administered in-line with NCPAP 
devices tested in this study. However, it is best accomplished by HFNC. Placement of the 
nebulizer prior to the humidifier increased deposition with all devices tested in this study. 
Clinical research is warranted to identify and select the proper CPAP device, interface, 
and administration technique to enhance clinical efficiency of aerosol therapy. 
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